• Users Online: 4044
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2015  |  Volume : 20  |  Issue : 1  |  Page : 55-59

Ketamine in treatment-resistant depression: A review of completed investigations

Department of Behavioral Health, Kaiser Permanente, Mid-Atlantic Permanente Medical Group, USA

Correspondence Address:
Shweta S Verma
Kaiser Permanente Behavioral Health, 5999 Burke Commons Road, Burke, VA 22015
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0971-9903.151741

Rights and Permissions

Background and Objective: The objective was to evaluate clinical trial data on the use of ketamine in treating treatment-resistant depression (TRD). Materials and Methods: PubMed search (November 2012) was initiated using the keywords: Ketamine, resistant depression. Inclusion criterion included: English language publications describing clinical trial reports on humans with TRD. Results: A total of 360 patients across 15 clinical trials with TRD were treated with infusional ketamine. On average 15-90% of patients reported a >50% decrease in their baseline Montgomery-Åsberg Depression Rating Scale/Hamilton Rating Scale for Depression scores at 4 h. Response rates decreased significantly as time progressed. Conclusion: Infusional ketamine has a significant rapid, short-term antidepressant effect in the treatment of TRD.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded451    
    Comments [Add]    
    Cited by others 1    

Recommend this journal